mipomersen
Sponsors
Kastle Therapeutics, LLC, Ludwig-Maximilians - University of Munich
Conditions
AtherosclerosisCongenital AbnormalitiesCoronary Heart DiseaseDyslipidemiasGenetic Diseases, InbornHealthy VolunteerHypercholesterolemiaHypercholesterolemia, Autosomal Dominant
Phase 1
A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers
CompletedNCT01061814
Start: 2010-01-31End: 2010-06-30Updated: 2016-08-03
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers
CompletedNCT01299298
Start: 2011-01-31End: 2011-04-30Updated: 2016-08-03
Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects
CompletedNCT01414881
Start: 2011-09-30End: 2012-11-30Updated: 2016-08-03
Phase 2
Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
CompletedNCT00362180
Start: 2006-07-31End: 2010-09-30Updated: 2016-10-21
Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
CompletedNCT00707746
Start: 2008-10-31End: 2011-01-31Updated: 2016-09-09
Phase 3
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
CompletedNCT00607373
Start: 2007-07-31End: 2009-03-31Updated: 2016-09-09
Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis
CompletedNCT00794664
Start: 2009-01-31End: 2010-10-31Updated: 2016-09-09
Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis
CompletedNCT01598948
Start: 2012-08-31End: 2015-06-30Updated: 2015-09-02